Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India

被引:1
|
作者
Chandy, Rachel G. [1 ]
Thomas, Vinotha [1 ]
Sebastian, Ajit [1 ]
Mani, Thenmozhi [2 ]
Thomas, Anitha [1 ]
Joel, Anjana [3 ]
Ram, Thomas S. [4 ]
Peedicayil, Abraham [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Gynaecol Oncol, Vellore, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, India
[3] Christian Med Coll & Hosp, Dept Med Oncol, Vellore, Tamil Nadu, India
[4] Christian Med Coll & Hosp, Dept Radiat Oncol, Vellore, Tamil Nadu, India
关键词
Ovarian cancer; survival; treatment; NEOADJUVANT CHEMOTHERAPY; PRIMARY SURGERY; CYTOREDUCTIVE SURGERY; RANDOMIZED-TRIAL; PATTERNS;
D O I
10.4103/ijc.IJC_496_20
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: One needs to choose wisely between primary neoadjuvant chemotherapy and primary cytoreductive surgery in ovarian cancer. The aim was to determine the recurrence free survival and overall survival after surgery for epithelial ovarian cancer and also the risk factors for recurrence and death.Methods: Electronic medical records of 322 women operated for ovarian, fallopian or primary peritoneal cancer between 2011 and 2015table were reviewed. Descriptive statistics were used to describe patients and their clinical outcomes. Cox proportional hazard models were used for risk factor analysis. Adjusted hazard ratios were obtained for recurrence and death, adjusted for stage, primary treatment modality, residual disease and histology. Kaplan-Meier curves were drawn for probability of recurrence-free survival and overall survival. The log rank test was used to compare survival probabilities.Results: The majority were stage III or stage IV (78%), serous histology (71%) and high grade (64%). Primary cytoreduction was done in 48% and interval cytoreduction in 52%. The median duration of follow up (survival) was 77 months (95% CI 72-82). There were 179 known recurrences (55.6 %). The estimated median time to recurrence was 22 (95% CI 14.5- 29.5) months. The independent risk factors for recurrence were neoadjuvant chemotherapy [HR 2.14, 95% CI 1.48-3.09], stage III/IV [HR 2.75; 95% CI 1.40-5.41], high grade serous histology [HR 1.69; 95% CI 1.12-2.54] and sub-optimal debulking [HR 3.15, 95% CI 2.19-4.55]. There were 78 known deaths (24.2 %) with a mean time to death of 24.3 (SD 16.1) months. The independent risk factors for death were sub-optimal debulking [HR 3.07; 95% CI 1.78-5.29] and stages III and IV cancer [HR 3.07; 95% CI 1.14-8.27].Conclusions: Most ovarian cancers recur within 2 years. Risk factors for mortality are advanced stage and sub-optimal debulking. Maximal efforts at down staging and surgical resection will increase survival.
引用
收藏
页码:475 / 485
页数:12
相关论文
共 50 条
  • [41] RETROSPECTIVE ANALYSIS OF PATIENTS WITH OVARIAN CANCER RECEIVING TREATMENT AT A TERTIARY CARE HOSPITAL IN INDIA
    Abraham, P. S.
    Greene, M.
    VALUE IN HEALTH, 2017, 20 (05) : A140 - A140
  • [42] Survival outcomes in ovarian cancer
    See, A. T. A.
    Drake, A. C.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 : 179 - 179
  • [43] Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India
    Gupta, Ankita
    Kumar, Divyesh
    Kaushal, Vikrant
    Miriyala, Raviteja
    Srinivasa, G. Y.
    Dey, Treshita
    Rai, Bhavana
    Das, Chandan K.
    Srinivasan, Radhika
    Gupta, Nalini
    Prasad, G. R., V
    Jain, Vanita
    Dey, Pranab
    Bagga, Rashmi
    Kalra, Jaswinder
    Saha, S. C.
    Rajwanshi, Arvind
    Suri, Vanita
    Ghoshal, Sushmita
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 18 (02)
  • [44] Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India
    Ankita Gupta
    Divyesh Kumar
    Vikrant Kaushal
    Raviteja Miriyala
    G. Y. Srinivasa
    Treshita Dey
    Bhavana Rai
    Chandan K. Das
    Radhika Srinivasan
    Nalini Gupta
    G. R. V. Prasad
    Vanita Jain
    Pranab Dey
    Rashmi Bagga
    Jaswinder Kalra
    S. C. Saha
    Arvind Rajwanshi
    Vanita Suri
    Sushmita Ghoshal
    Indian Journal of Gynecologic Oncology, 2020, 18
  • [45] Thorax trauma severity score in patient with chest trauma: study at tertiary-level hospital
    Kanake, Vijay
    Kale, Karan
    Mangam, Shubhangi
    Bhalavi, Vijay
    INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 38 (02) : 149 - 156
  • [46] EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF NONCONVULSIVE STATUS EPILEPTICUS IN A TERTIARY-LEVEL HOSPITAL IN THE NORTHWEST OF SPAIN
    Fernandez-Ferro, J.
    Moreno, E.
    Pardo, J.
    Peleteiro, M.
    Rodriguez-Osorio, X.
    Lopez, F.
    Corredera, E.
    Lema, M.
    EPILEPSIA, 2010, 51 : 49 - 49
  • [47] Outcomes of patients with epithelial ovarian cancer in a private versus public hospital setting
    Pua, T. L.
    Arslan, A. A.
    Curtin, J. P.
    Blank, S. V.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S152 - S152
  • [48] Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital
    Peeyananjarassri, Krantarat
    Nanthamongkolkul, Kulisara
    Jiamset, Ingporn
    Chusook, Wuttipong
    Boonyapipat, Sathana
    Buhachat, Rakchai
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2023, 162 (01) : 317 - 324
  • [49] Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
    Ma, Mirielle C.
    Lavi, Ethan S.
    Altwerger, Gary
    Lin, Z. Ping
    Ratner, Elena S.
    PLOS ONE, 2024, 19 (07):
  • [50] Survival Outcomes With Reduced Doses of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    Lee, Juhun
    Kim, Jong Mi
    Lee, Yoon Hee
    Chong, Gun Oh
    Hong, Dae Gy
    IN VIVO, 2022, 36 (04): : 1868 - 1874